血清恶性肿瘤特异性生长因子对原发性肝癌介入治疗的疗效评估价值

目的 明确血清恶性肿瘤特异性生长因子(TSGF)对原发性肝癌介入治疗的疗效评估价值。 方法 纳入2015年1月-2017年1月在新疆医科大学第一附属医院接受肝癌动脉灌注化疗栓塞治疗的原发性肝癌患者的临床资料。依据单次介入手术治疗后是否有效分为观察组(有效,治疗后肿瘤体积缩小≥ 50%)及对照组(无效,治疗后肿瘤体积缩小<50%)。共纳入84例患者,其中观察组患者49例,对照组患者35例。检测并对比2组患者治疗前及治疗后7 d外周血TSGF及甲胎蛋白(AFP)的改变,分析各项指标对患者单次治疗的疗效评估价值。 结果 2组患者治疗后TSGF、AFP水平与治疗前比较均显著降低(P<0.05),且观察组患者显著低于对照组(P<0.05);观察组患者治疗前后TSGF下降水平(ΔTSGF)显著高于对照组患者(86.7±11.2) U/ml vs.(50.4±9.6) U/ml;t=13.900,P<0.01];观察组患者治疗前后AFP下降水平(ΔAFP)显著高于对照组患者(351.9±15.3) ng/ml vs.(296.8±12.9) ng/ml;t=13.390,P<0.01]。ROC曲线分析显示,以79.33 U/ml为截点值,治疗后7 d ΔTSGF预测单次介入治疗有效的敏感性为88.57%,特异性为83.67%,曲线下面积为0.882,优于ΔAFP。相关性分析提示,ΔTSGF与ΔAFP呈现显著正相关关系(r=0.676,P<0.01)。 结论 TSGF对原发性肝癌介入治疗的有效性具有一定评估价值,优于传统的AFP。 

The efficacy prediction diagnostic value of tumor specific growth factor for primary hepatic carcinoma patients received transcatheter arterial chemoembolization

Objective To analyze the efficacy prediction diagnostic value of tumor specific growth factor (TSGF) for primary hepatic carcinoma patients received transcatheter arterial chemoembolization (TACE). Methods Clinical data of primary hepatic carcinoma patients received transcatheter arterial chemoembolization treatment at our hospital from 2015 to 2017 were analyzed. Patients were divided into two groups by therapeutic effect, Group A:effective, n=49; Group B:invalid, n=35. AFP and TSGF were tested before and 7 days after TACE, the efficacy prediction diagnostic value was analyzed by ROC. Results Seven days after treatment, both groups got significantly decreased in AFP and TSGF (P<0.05). However, these index were lower in Group A when compared with those of Group B (P<0.05). Meanwhile, patients in group A had higher change rate of TSGF (ΔTSGF) and ΔAFP when compared with these of group BΔTSGF:(86.7±11.2)U/ml vs. (50.4±9.6)U/ml, t=13.900, P<0.01; ΔAFP:(351.9±15.3)ng/ml vs. (296.8±12.9)ng/ml, t=13.390, P<0.01]. ROC analysis showed that the ΔTSGF cut-off point value of 79.33 U/ml, as used for the prediction of effective TACE treatment, provided a sensitivity of 88.57%, a specificity of 83.67%, an AUC of 0.882,better than these of ΔAFP. Correlation analysis showed that, for patients in group A, the levels of ΔTSGF had significant positive correlation with ΔAFP (r=0.676, P<0.01). Conclusion The TSGF can be used as an efficacy prediction diagnostic index for primary hepatic carcinoma patients received treatment of TACE.